Thu, May 8, 10:56 AM (4 days ago)
**ZURA BIO LIMITED (ZURA) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** ZURA reported no revenue for Q1 2025, consistent with its clinical-stage status. - **Profit Margins:** The company incurred a net loss of $17.4 million for Q1 2025, compared to $7.7 million in Q1 2024, reflecting increased operating expenses. - **Cash Flow:** Net cash used in operating activities was $11.1 million, up from $5.0 million in Q1 2024. The company ended Q1 2025 with $170.6 million in cash and cash equivalents. - **Earnings Changes:** The net loss attributable to Class A Ordinary Shareholders increased significantly to $17.4 million from $730,000 in Q1 2024. **Operational Metrics:** - **Operating Expenses:** Total operating expenses rose by 130% to $19.3 million, driven by increased research and development (R&D) and general and administrative (G&A) costs. - **R&D Expenses:** Increased by 192% to $10.5 million, primarily due to clinical trial execution fees and manufacturing costs. - **G&A Expenses:** Increased by 83% to $8.8 million, mainly due to higher compensation and professional fees. **Quarterly Performance Discussion:** - **Tibulizumab (ZB-106):** Ongoing Phase 2 trials for systemic sclerosis (SSc) and planned initiation for hidradenitis suppurativa (HS). - **Crebankitug (ZB-168) and Torudokimab (ZB-880):** Continued evaluation of therapeutic indications and competitive landscape. **Trends and Uncertainties:** - **Funding:** ZURA has sufficient liquidity to fund operations through 2027, but future financing will depend on clinical development progress and market conditions. - **Regulatory and Market Risks:** Global economic trends, trade policies, and regulatory approvals pose uncertainties that could impact operational performance and financial condition. **Future Operations Impact:** - **Clinical Development:** Continued investment in R&D and clinical trials is expected to drive future growth. - **Commercialization:** Potential regulatory approvals and commercialization efforts will require significant additional capital and strategic planning. **Conclusion:** ZURA Bio Limited continues to advance its clinical-stage product candidates, with a focus on dual-pathway antibodies for autoimmune and inflammatory diseases. The company's financial performance reflects substantial investments in R&D and G&A, with a strategic emphasis on securing future financing to support ongoing and planned clinical trials.